TABLE 1.
Author, year | Country centers setting | Inclusion criteria | Exclusion criteria | Randomized, n (P/no P) | Trial outcomes | Follow‐up |
---|---|---|---|---|---|---|
Assir et al., 2013 |
Pakistan 1 Dengue HDU |
Adults ≥ 14 years, dengue fever or dengue hemorrhagic fever, platelet counts < 30 × 109/L, no or mild bleeding (WHO grade 1 or 2) | Other causes of thrombocytopenia, chronic ailments, history of platelet transfusion, severe bleeding (WHO grade 3 or 4) | 48 a (21/24) |
Primary:
Secondary:
|
72 h for the primary outcomes. Follow‐up for secondary outcomes unclear. |
Grossman et al., 1980 |
Canada 1 Hospital ward |
Patients with amegakaryocytic thrombocytopenia, platelet counts less than 50 × 109/L | Refractory to platelet transfusions, not candidate for aggressive therapy, thrombocytopenia not expected to last for more than 7 days | 100 (49/51) |
Primary: Not specified
Secondary:
|
Unclear. Patients were followed throughout their initial hospital stay and all subsequent admissions, (mean length of follow‐up was 42.7 days in the P‐group and 41.6 days in the no P‐group). |
Lye et al., 2017 |
Singapore, Malaysia 5 Hospital ward b |
Patients ≥ 21 years, probable or confirmed dengue (WHO 1997 or 2009 criteria), platelet count ≤20 × 109/L | Platelet count > 20 × 109/L, signs of clinical bleeding, pregnancy, lactating women, history of severe reactions to blood product transfusion, prior platelet transfusion within the same illness episode, patients likely to die within 48 h, history of peptic ulcer within 3 months, anticoagulants' use within 4 weeks, chronic liver disease, chronic renal failure or dialysis, active hematological or autoimmune disease, non‐availability of platelet supply from local blood bank, consent unobtainable | 372 (188/184) |
Primary:
Secondary:
|
21 days |
Murphy et al., 1982 |
USA 1 Hospital ward b |
Children with previously untreated acute leukemia | Not reported | 56 (35/21) |
Primary: Not specified
Secondary:
|
Unclear. Patients were followed from study entry until death or study closure (mean length of follow‐up was 19.9 months in the P‐group and 20.4 in the no P‐group). |
Sintnicolaas et al., 1981 |
Netherlands 1 b Hospital ward b |
Patients with acute leukemia and severe thrombocytopenia | Not reported | 12 c (?/?) |
Primary: Not specified
Secondary:
|
Unclear |
Solomon et al., 1978 |
USA 1 b Hospital ward b |
Patients with previously untreated non‐lymphoblastic acute leukemia | Promyelocytic leukemia | 31 (19/12) |
Primary: Not specified
Secondary:
|
Within 1 month of chemotherapy course |
Stanworth et al., 2013 |
United Kingdom, Australia 14 Hospital ward |
Patients ≥ 16 years, undergoing chemotherapy or stem‐cell transplantation to treat a hematological cancer, platelet count < 50 × 109/L or expected to be so for at least 5 days, able to comply with treatment and monitoring | Previous WHO grade 3 or 4 bleeding, WHO grade 2 bleeding during current admission, inherited hemostatic or thrombotic disorder, requirement for therapeutic doses of anticoagulant agents, acute promyelocytic leukemia, known HLA antibodies, pregnancy, prior randomization into the trial | 600 (299/301) |
Primary:
Secondary:
|
30 days |
Wandt et al., 2012 |
Germany 8 Hospital ward |
Patients 16–80 years, undergoing intensive chemotherapy for acute myeloid leukemia or autologous haemopoietic stem‐cell transplantation for hematological cancers | Refractory to platelet transfusions, previous major bleeding, plasmatic coagulopathy, pulmonary or cerebral lesions (stem‐cell transplantations only) | 396 (197/199) |
Primary:
Secondary:
|
Unclear. The study was completed when the platelet count was self‐sustaining at more than 20 × 109 per L for 2 days or a maximum of 30 days, at hospital discharge, when treatment failure was diagnosed, at death, or at study withdrawal, which ever occurred first. |
NCT03713489 (Ongoing) |
China 1 Unclear |
Patients 18–60 years, diagnosed with acute‐on‐chronic liver failure and chronic hepatitis B infection and ADP inhibition of ≥70% |
Other causes of chronic live disease than chronic hepatitis B infection, previous decompensation, intracranial hemorrhage, use of anti‐platelet or anticoagulants therapy within 4 weeks, esophageal variceal bleeding within 1 week, platelet transfusion within 1 week, malignant disease, pregnancy or breastfeeding, severe chronic extra‐hepatic disease. Considered not suitable for inclusion by researchers. |
Estimated enrolment: 20 |
Primary:
Secondary:
|
28 days for the primary outcome. Unclear for the secondary outcome. |
van de Weerdt et al. (Ongoing) |
Netherlands 11 Hospital ward/ICU |
Adult (≥18 years) hematologic or ICU patients with thrombocytopenia (10–50 × 109/L) scheduled for emergency or elective insertion or replacement of a central line and an expectation of the inserted line to be in situ for at least 24 h | Patients with a non‐correctable INR < 1.5, history of congenital or acquired coagulation factor deficiency or bleeding diathesis, treatment with double platelet‐aggregation inhibitors or therapeutic unfractionated heparin not discontinued at least 1 h prior to insertion | Planned enrolment: 392 (196/196) |
Primary:
Secondary:
|
28 days |
Abbreviations: ADP, adenosine diphosphate; CVC, central venous catheter; HDU, high dependency unit; HEME, hemorrhage measurement; HLA, human leukocyte antigen; ICU, intensive care unit; INR, international normalized ratio; P, prophylaxis; RBC, red blood cells; WHO, World Health Organization.
Eighty‐seven patients were randomized but 39 patients had bleeding (WHO grade 1 or 2) at randomization and were ineligible for this review.
Assumption; not clearly reported.
Allocation to intervention groups not reported.